De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria

Antimicrobial peptides (AMPs) have been identified as a potentially new class of antibiotics to combat bacterial resistance to conventional drugs. The design of de novo AMPs with high therapeutic indexes, low cost of synthesis, high resistance to proteases and high bioavailability remains a challeng...

Full description

Bibliographic Details
Main Authors: Boris Vishnepolsky, George Zaalishvili, Margarita Karapetian, Tornike Nasrashvili, Nato Kuljanishvili, Andrei Gabrielian, Alex Rosenthal, Darrell E. Hurt, Michael Tartakovsky, Maya Grigolava, Malak Pirtskhalava
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/12/2/82
id doaj-43a817c4693e4e8bba1a64e1e77fc011
record_format Article
spelling doaj-43a817c4693e4e8bba1a64e1e77fc0112020-11-25T01:22:54ZengMDPI AGPharmaceuticals1424-82472019-06-011228210.3390/ph12020082ph12020082De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative BacteriaBoris Vishnepolsky0George Zaalishvili1Margarita Karapetian2Tornike Nasrashvili3Nato Kuljanishvili4Andrei Gabrielian5Alex Rosenthal6Darrell E. Hurt7Michael Tartakovsky8Maya Grigolava9Malak Pirtskhalava10Ivane Beritashvili Center of Experimental Biomedicine, 0160 Tbilisi, GeorgiaLabarotory of Animal Molecular Biology, Agricultural University of Georgia, 240 David Aghmashenebeli Alley, 0159 Tbilisi, GeorgiaLabarotory of Animal Molecular Biology, Agricultural University of Georgia, 240 David Aghmashenebeli Alley, 0159 Tbilisi, GeorgiaLabarotory of Animal Molecular Biology, Agricultural University of Georgia, 240 David Aghmashenebeli Alley, 0159 Tbilisi, GeorgiaLabarotory of Animal Molecular Biology, Agricultural University of Georgia, 240 David Aghmashenebeli Alley, 0159 Tbilisi, GeorgiaOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAIvane Beritashvili Center of Experimental Biomedicine, 0160 Tbilisi, GeorgiaIvane Beritashvili Center of Experimental Biomedicine, 0160 Tbilisi, GeorgiaAntimicrobial peptides (AMPs) have been identified as a potentially new class of antibiotics to combat bacterial resistance to conventional drugs. The design of de novo AMPs with high therapeutic indexes, low cost of synthesis, high resistance to proteases and high bioavailability remains a challenge. Such design requires computational modeling of antimicrobial properties. Currently, most computational methods cannot accurately calculate antimicrobial potency against particular strains of bacterial pathogens. We developed a tool for AMP prediction (Special Prediction (SP) tool) and made it available on our Web site (https://dbaasp.org/prediction). Based on this tool, a simple algorithm for the design of de novo AMPs (DSP) was created. We used DSP to design short peptides with high therapeutic indexes against gram-negative bacteria. The predicted peptides have been synthesized and tested in vitro against a panel of gram-negative bacteria, including drug resistant ones. Predicted activity against <i>Escherichia coli ATCC 25922</i> was experimentally confirmed for 14 out of 15 peptides. Further improvements for designed peptides included the synthesis of D-enantiomers, which are traditionally used to increase resistance against proteases. One synthetic D-peptide (SP15D) possesses one of the lowest values of minimum inhibitory concentration (MIC) among all DBAASP database short peptides at the time of the submission of this article, while being highly stable against proteases and having a high therapeutic index. The mode of anti-bacterial action, assessed by fluorescence microscopy, shows that SP15D acts similarly to cell penetrating peptides. SP15D can be considered a promising candidate for the development of peptide antibiotics. We plan further exploratory studies with the SP tool, aiming at finding peptides which are active against other pathogenic organisms.https://www.mdpi.com/1424-8247/12/2/82antimicrobial peptidespredictive modelsdrug design
collection DOAJ
language English
format Article
sources DOAJ
author Boris Vishnepolsky
George Zaalishvili
Margarita Karapetian
Tornike Nasrashvili
Nato Kuljanishvili
Andrei Gabrielian
Alex Rosenthal
Darrell E. Hurt
Michael Tartakovsky
Maya Grigolava
Malak Pirtskhalava
spellingShingle Boris Vishnepolsky
George Zaalishvili
Margarita Karapetian
Tornike Nasrashvili
Nato Kuljanishvili
Andrei Gabrielian
Alex Rosenthal
Darrell E. Hurt
Michael Tartakovsky
Maya Grigolava
Malak Pirtskhalava
De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
Pharmaceuticals
antimicrobial peptides
predictive models
drug design
author_facet Boris Vishnepolsky
George Zaalishvili
Margarita Karapetian
Tornike Nasrashvili
Nato Kuljanishvili
Andrei Gabrielian
Alex Rosenthal
Darrell E. Hurt
Michael Tartakovsky
Maya Grigolava
Malak Pirtskhalava
author_sort Boris Vishnepolsky
title De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
title_short De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
title_full De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
title_fullStr De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
title_full_unstemmed De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria
title_sort de novo design and in vitro testing of antimicrobial peptides against gram-negative bacteria
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2019-06-01
description Antimicrobial peptides (AMPs) have been identified as a potentially new class of antibiotics to combat bacterial resistance to conventional drugs. The design of de novo AMPs with high therapeutic indexes, low cost of synthesis, high resistance to proteases and high bioavailability remains a challenge. Such design requires computational modeling of antimicrobial properties. Currently, most computational methods cannot accurately calculate antimicrobial potency against particular strains of bacterial pathogens. We developed a tool for AMP prediction (Special Prediction (SP) tool) and made it available on our Web site (https://dbaasp.org/prediction). Based on this tool, a simple algorithm for the design of de novo AMPs (DSP) was created. We used DSP to design short peptides with high therapeutic indexes against gram-negative bacteria. The predicted peptides have been synthesized and tested in vitro against a panel of gram-negative bacteria, including drug resistant ones. Predicted activity against <i>Escherichia coli ATCC 25922</i> was experimentally confirmed for 14 out of 15 peptides. Further improvements for designed peptides included the synthesis of D-enantiomers, which are traditionally used to increase resistance against proteases. One synthetic D-peptide (SP15D) possesses one of the lowest values of minimum inhibitory concentration (MIC) among all DBAASP database short peptides at the time of the submission of this article, while being highly stable against proteases and having a high therapeutic index. The mode of anti-bacterial action, assessed by fluorescence microscopy, shows that SP15D acts similarly to cell penetrating peptides. SP15D can be considered a promising candidate for the development of peptide antibiotics. We plan further exploratory studies with the SP tool, aiming at finding peptides which are active against other pathogenic organisms.
topic antimicrobial peptides
predictive models
drug design
url https://www.mdpi.com/1424-8247/12/2/82
work_keys_str_mv AT borisvishnepolsky denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT georgezaalishvili denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT margaritakarapetian denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT tornikenasrashvili denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT natokuljanishvili denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT andreigabrielian denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT alexrosenthal denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT darrellehurt denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT michaeltartakovsky denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT mayagrigolava denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
AT malakpirtskhalava denovodesignandinvitrotestingofantimicrobialpeptidesagainstgramnegativebacteria
_version_ 1725124861577134080